Mumbai, India – December 5, 2025 – ImmunoACT, the pioneering Mumbai-based cell and gene therapy company, today announced a strategic partnership with Mango Sciences, Inc., the Boston and Bengaluru-based data and AI leader, to revolutionize access to its groundbreaking NexCAR19™ CAR-T therapy for leukaemia and lymphoma patients in India.
This collaboration introduces the world’s first bridge financing plan, offering eligible patients 0% interest EMI options up to ₹10 lakhs to cover therapy costs. Additionally, a value-based offering of up to ₹10 lakhs is available for clinically eligible patients, tying financial support to treatment outcomes and demonstrating ImmunoACT’s confidence in NexCAR19™’s efficacy and safety.
NexCAR19™, India’s first approved CAR-T therapy (Talicabtagene autoleucel), received Market Authorization from the Central Drugs Standard Control Organization (CDSCO) in October 2023. Developed from incubation at IIT Bombay, it provides an affordable, lifesaving alternative to traditional chemotherapy, biologics, and bone marrow transplants initially available at select healthcare facilities.
“We are delighted to partner with Mango Sciences to improve access and affordability for patients needing NexCAR19™,” said Dr. Rahul Purwar, Founder of ImmunoACT. “These outcome-based programs will significantly help patients afford our therapy, reflecting our strong evidence of its efficacy and safety while advancing our mission to deliver novel CAR-T therapies at scale.”
Dr. Mohit Misra, Founder & CEO of Mango Sciences, added, “We are excited to bring our value-based offerings to CAR-T a global first. Together with ImmunoACT, we’re using data science and technology to ensure more patients access cutting-edge oncology innovations and better cancer outcomes.”
ImmunoACT is expanding its pipeline from blood cancers to solid tumours and autoimmune disorders, empowering medical professionals with effective, patient-centric therapies.
About ImmunoACT ImmunoACT (Immunoadoptive Cell Therapy Private Limited) is India’s first fully integrated CAR-T cell therapy company, developing and manufacturing accessible, affordable gene-modified cell therapies for blood cancers and solid tumours.
Its lead product, NexCAR19™, developed in collaboration with IIT Bombay and Tata Memorial Centre, is India’s first commercially approved CAR-T cell therapy and has transformed outcomes in relapsed/refractory B-cell malignancies. ImmunoACT’s pipeline includes a BCMA-directed CAR-T therapy for multiple myeloma and several solid tumour CAR-T programs under development. The company is expanding global access through strategic international partnerships. For more information, visit www.immunoact.com.
Media Contact: helpdesk@immunoact.com